DOCSLIB.ORG

New Zealand Regulatory Guidelines for Medicines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

New Zealand Regulatory Guidelines for Medicines Part G: Resources Edition 6.13 March 2011 (consolidation of fifth edition and subsequent updates) Table of Contents PART G: RESOURCES Section 1: Description of Dosage Form...............................................................................2 Section 2: Routes of Administration....................................................................................4 Section 3: Shelf Life and Storage Conditions .....................................................................5 Section 4: Abbreviations.......................................................................................................6 Description of Dosage Form The dosage form description for a product should be selected from the following list: Block Granules, oral Capsule Implant, subcutaneous Capsule, combination Implant, intracranial Capsule, liquid filled Implant, intraocular Capsule, modified release Infusion, concentrate Capsule, powder filled Infusion, emulsion Capsule, powder filled, nasal inhalation Infusion, powder for Capsule, soft gelatin Infusion, powder for concentrate Cement, bone, liquid component Infusion, solution Cement, bone, powder component Inhalation, capsule, liquid filled Cement, dental Inhalation, capsule, powder filled Chewing gum Inhalation, powder Chocolate, medicated Inhalation, solution Combination Inhalation, solution, powder for Condom, medicated Inhalation, suspension Condom with spermicide Inhalation, volatile liquid Cream, rectal Inhaler, aerosol, metered Cream, topical Injection with diluent Cream, vaginal Injection, concentrate Crystals Injection, depot Dermal patch, local effect Injection, emulsion Diluent Injection, gel Dressing, medicated Injection, granules for Drops, ear Injection, powder for Drops, ear/eye Injection, solution Drops, ear/eye/nose Injection, suspension Drops, eye, powder and diluent Intrauterine contraceptive device Drops, eye, solution Irrigation Drops, eye, suspension Irrigation, eye Drops, nasal Irrigation, powder for reconstitution. Drops, oral Lacquer, nail Elixir Linctus Emulsion, oral Liniment Emulsion, topical Lotion, scalp Enema Lotion, skin Enema, powder for Lozenge Eye strip, impregnated Mouthwash, solution Foam Mouthwash, solution, powder for Gas Oil Gel, ophthalmic Oil, bath Gel, oral Oil, topical Gel, oral topical Ointment, ear/eye Gel, topical Ointment, eye Gel, vaginal Ointment, rectal Granules, effervescent Ointment, topical Granules, modified release Ointment, vaginal New Zealand Regulatory Guidelines for Medicines (Volume 1, Edition 6.131, 2011) Part G: Resources Page 2 Pad, skin wash impregnated Suppository Paste, oral Suppository, urethral Paste, topical Suspension, intratracheal Pastille Suspension, intratracheal, powder for Pessary Suspension, oral Plant material Suspension, oral, granules for Powder Suspension, oral, powder for Powder, effervescent Suspension, rectal/oral Powder, nasal Syrup Powder, topical Syrup, powder for Shampoo Tablet Skin wash Tablet for contact lens solution Soap Tablet, chewable Solution Tablet, chewable/dispersible Solution, antiseptic Tablet, coated Solution, contact lens Tablet, dispersible Solution, dialysis Tablet, effervescent Solution, dialysis, powder for Tablet, enteric coated Solution, oral Tablet, film coated Solution, oral, granules for Tablet, modified release Solution, oral, powder for Tablet, orodispersible Solution, topical Tablet, soluble Solution, topical, powder for Tablet, sublingual Solution, vaginal douche Tablet, uncoated Sponge, vaginal Tablet, vaginal Spray, contact lens solution Test kit Spray, nasal solution Test kit, pregnancy Spray, nasal suspension Toothpaste Spray, oral Transdermal gel Spray, sublingual Transdermal patch Spray, topical Transdermal patch, systemic effect Spray, topical powder Vaginal ring Stick, topical Wafer New Zealand Regulatory Guidelines for Medicines (Volume 1, Edition 6.131, 2011) Part G: Resources Page 3 Routes of Administration The description of the route of administration for a product should be selected from the following list: Conjunctival Intrasternal Cutaneous Intrauterine Dental Intrathecal Endocervical Intratracheal Endosinusial Intravenous Epidural Intravesical Extra-amniotic Irrigation Gingival Nasal Haemodialysis Implant Opthalmic Inhalation Oral Insufflation Oromucosal Intra-amniotic Otic Intra-arterial Periarticular Intra-articular Perineural Intrabursal Periodontal Intracardiac Peri-osteal Intracavernous Rectal Intracervical Subconjunctival Intracoronary Subcutaneous Intradermal Sublingual Intradiscal Submucosal Intralesional Systemic Intralymphatic Transdermal Intramuscular Transmammary transfer Intraocular Ungula Intraperitoneal Urethral Intrapleural Vaginal New Zealand Regulatory Guidelines for Medicines (Volume 1, Edition 6.131, 2011) Part G: Resources Page 4 Shelf Life and Storage Conditions The claimed shelf life must be supported by stability studies. Such studies should meet the requirements of the ICH guidelines for stability testing. If specific storage conditions are required, the storage conditions statement should be selected or compounded using elements from the following list (or words of similar meanings): protect from light at 8° to 15°C (Cool) protect from moisture at 15° to 25°C (Controlled room temperature) below -20°C (Deep freeze) at or below 25°C below -5°C (Freeze) below 30°C at 2° to 8°C (Refrigerate, do not freeze) Use immediately Note that in New Zealand “below 25°C” means room temperature, whereas in Australia “below 25°C” refers to air-conditioned facilities and “below 30°C” refers to room temperature. Summary of Special Requirements [Also add matrix to show a list of medicines that need specific labelling requirements and warnings for data sheets. Example:] Medicine or Ingredient Labelling Requirements Data Sheet Requirement New Zealand Regulatory Guidelines for Medicines (Volume 1, Edition 6.131, 2011) Part G: Resources Page 5 Abbreviations AAN Australian Approved Name ADEC Australian Drug Evaluation Committee ADR Adverse drug reaction Ae Cumulative urinary recovery ANOVA Analysis of variance API Active pharmaceutical ingredient ARTG Australian Register of Therapeutic Goods AUC Area under the concentration vs. time curve AUC∞ AUC up to the last quantifiable concentration plus additional area extrapolated to infinity, calculated using kel AUCt Area under the concentration vs. time curve (AUC) measured to the last quantifiable concentration AUCTCSS AUC measured over one dose interval (T) at steady state AUCTS AUC over the dosing interval (T) following a single dose of the MR product AUCTS/AUC∞ Ratio of AUC over the dosing interval to the total AUC BAN British Approved Name BNF British National Formulary BP British Pharmacopoeia CARM Centre for Adverse Reactions Monitoring Cav Average concentration CFC Chlorofluorocarbon Cmax Maximum observed concentration CMI Consumer Medicine Information Cmin Minimum observed concentration CMN Changed Medicine Notification CoS Certificate of Suitability (European Pharmacopoeial Commission) Cpd Pre-dose concentration determined immediately pre-dose CHMP Committee for Medicinal Products for Human Use (formerly known as CPMP Committee for Proprietary Medicinal Products) [Europe] CPP Certificate of a Pharmaceutical Product CRPN Changed Related Product Notification Ct The last quantifiable concentration CTD Common Technical Document (ICH format) DF Degree of fluctuation = (Cmax - Cmin)/ (AUCT/T) x 100% DMF Drug Master File EC European Community; or European Commission; or Enteric-coated EMEA European Medicines Evaluation Agency EP [See Ph Eur] New Zealand Regulatory Guidelines for Medicines (Volume 1, Edition 6.131, 2011) Part G: Resources Page 6 ERMA Environmental Risk Management Authority EU European Union FDA Food and Drug Administration [USA] FEV1 Forced expiry volume in 1 second GC Gas chromatography GCRP Good Clinical Research Practice GMP Good Manufacturing Practice GSC Generics Subcommittee of MAAC HPLC High pressure (or performance) liquid chromatography HRC Health Research Council HSNO Hazardous Substances and New Organisms Act ICH International Conference on Harmonisation IMM Interchangeable Multi-source Medicine IMMP Intensive Medicines Monitoring Programme INN International Non-proprietary Name kel Terminal elimination rate constant MAAC Medicines Assessment Advisory Committee MARC Medicines Adverse Reactions Committee MCA Medicines Control Agency [UK]; or Medicines Control Advisor MCC Medicines Classification Committee MOH Medical Officer of Health MoH Ministry of Health MoU Memorandum of Understanding MQC Minimum quantifiable concentration MR Modified release MRC Medicines Review Committee MRT Mean residence time NBE New Biological Entity NCE New Chemical Entity NF National Formulary [USA] NMA New Medicine Application NMA-H New higher-risk medicine application NMA-I New intermediate-risk medicine application NMA-L New lower-risk medicine application NRL National Radiation Laboratory NRPA New Related Product Application NSAID Non-Steroidal Anti-Inflammatory Drug NZ New Zealand NZRGM New Zealand Regulatory Guidelines for Medicines NZRP New Zealand Reference Product OIA Official Information Act OTC Over The Counter [i.e. non- prescription products] New Zealand Regulatory Guidelines for Medicines (Volume 1, Edition 6.131, 2011) Part G: Resources Page 7 Part I Administrative/summary section of European dossier Part II Chemistry & pharmaceutical section of European dossier Part III Pharmaco-toxicological section of European dossier Part IV Clinical section
Recommended publications
  • AP Suspension and Powder

    AP Suspension and Powder

    AP Suspension and Powder • Easily application and distribution • Ultrafine surface • Excellent stability Struers AP Suspensions and Powders are based on ultra pure aluminium oxides (alumina). They are available in two forms, Struers ApS deagglomerated and agglomerated. Pederstrupvej 84 DK-2750 Ballerup, Denmark Phone +45 44 600 800 Fax +45 44 600 801 [email protected] www.struers.com AUSTRALIAN & NEW ZEALAND NETHERLANDS Struers Australia Struers GmbH Nederland 27 Mayneview Street Zomerdijk 34 A Milton QLD 4064 3143 CT Maassluis Australia Telefoon +31 (10) 599 7209 Phone +61 7 3512 9600 Fax +31 (10) 5997201 Fax +61 7 3369 8200 [email protected] [email protected] NORWAY BELGIUM (Wallonie) Struers ApS, Norge Deagglomerated Agglomerated Struers S.A.S. Sjøskogenveien 44C 370, rue du Marché Rollay 1407 Vinterbro F- 94507 Champigny Telefon +47 970 94 285 Deagglomerated sur Marne Cedex [email protected] Téléphone +33 1 5509 1430 AP-D, deagglomerated aluminas are premium polishing abrasive and are agglomerate-free. The uniform Télécopie +33 1 5509 1449 AUSTRIA [email protected] Struers GmbH crystals ensure an ultrafine surface. Zweigniederlassung BELGIUM (Flanders) Österreich Struers GmbH Nederland Betriebsgebiet Puch Nord 8 Agglomerated Zomerdijk 34 A 5412 Puch 3143 CT Maassluis Telefon +43 6245 70567 AP-A, agglomerated aluminas are easily broken down during the polishing process while still providing Telefoon +31 (10) 599 7209 Fax +43 6245 70567-78 Fax +31 (10) 5997201 [email protected] faster initial stock removal. [email protected] POLAND CANADA Struers Sp. z o.o. Alumina powders Struers Ltd. Oddział w Polsce 7275 West Credit Avenue ul. Jasnogórska 44 Alumina powders consist of uniform particles with a narrow particle size distribution.
  • (12) United States Patent (10) Patent No.: US 7.427.405 B2 Agrawal Et Al

    (12) United States Patent (10) Patent No.: US 7.427.405 B2 Agrawal Et Al

    USOO7427405B2 (12) United States Patent (10) Patent No.: US 7.427.405 B2 Agrawal et al. (45) Date of Patent: Sep. 23, 2008 (54) IMMUNOSTIMULATORY Tokunaga et al., “Antitumor Activity of Deoxyribonucleic Acid Frac OLGONUCLEOTDE MULTIMERS tion from Mycobaterium bovis BCG. I. Isolation. Physicochemical Characterization, and Antitumor Activity”. J. Natl. Cancer Inst. 72: (75) Inventors: Sudhir Agrawal, Shrewsbury, MA (US); 955-962(1984). Pisetsky et al., “Stimulation of in vitro proliferation of murine lym Ekambar Kandimala, Southboro, MA phocytes by synthetic oligodeoxynucleotides'. Molecular Biology (US); Dong Yu, Westboro, MA (US) Reports 18:217-221 (1993). Krieg et al., “CpG motifs in bacterial DNA trigger direct B-cell (73) Assignee: Idera Pharmaceuticals, Inc., activation”, Nature 374: 546-549 (1995). Cambridge, MA (US) Sato et al., “Immunostimulatory DNA Sequence Necessary for Effective Intradermal Gene Immunization', Science 273: 352-354 (*) Notice: Subject to any disclaimer, the term of this (1996). patent is extended or adjusted under 35 Krieg et al., “CpG Motifs in Bacterial DNA and their Immune U.S.C. 154(b) by 209 days. Effects”, Annu. Rev. Immunol. 20: 709-760 (2002). Dalpke et al., “Immunopharmacology of CpG DNA'. Biol. Chem. (21) Appl. No.: 11/174,282 383: 1491-1500 (2002). Kandimala et al., “Towards Optimal Design of Second-Generation (22) Filed: Jul. 1, 2005 Immunomodulatory Oligonucleotides'. Curr. Opin. Mol. Ther. 4(2): 122-129 (2002). (65) Prior Publication Data Kandimala et al., “Immunomers-novel 3'-3'-Linked CpG Oligodeoxyribonucleotides as Potent Immunomodulatory Agents'. US 2006/OO19919 A1 Jan. 26, 2006 Nucleic Acids Res. 30: 4460-4469 (2002). Kandimala et al.
  • Journal of Arthroscopy and Joint Surgery 6 (2019) 98E102

    Journal of Arthroscopy and Joint Surgery 6 (2019) 98E102

    Journal of Arthroscopy and Joint Surgery 6 (2019) 98e102 Contents lists available at ScienceDirect Journal of Arthroscopy and Joint Surgery journal homepage: www.elsevier.com/locate/jajs Comparative evaluation of periarticular infiltration of two cocktail regimens for analgesia in post-operative patients of total knee replacement * V.K. Gautam a, Ajeet Kumar a, Munisha Agarwal b, Bushu Harna a, , Rishabh Saini a, Siddharth Sharma a, Dhananjaya Sabat a a Dept. of Orthopaedics, Maulana Azad Medical College, New Delhi, India b Dept. of Anaesthesia, Maulana Azad Medical College, New Delhi, India article info abstract Article history: Purpose: To compare the efficacy of two periarticular cocktail regimens for analgesia in postoperative Received 30 April 2018 patients of total knee replacement. Received in revised form Method: This is a Randomized Control study done over the duration of 1.5 years. Twenty-five knees of 28 October 2018 either gender were selected with inclusion criteria (All osteoarthritis patients planned for TKA) and Accepted 9 November 2018 exclusion criteria (Inflammatory arthritis, patients allergic to local anaesthetic e.g. Ropivacaine, bupi- Available online 19 November 2018 vacaine, known cardiac disorder patient having AV block, arrhythmia) & divided into 2 groups. Group A was given a cocktail of Ropivacaine, adrenaline, clonidine & cefuroxime. Keywords: & Periarticular Group B was given a cocktail of bupivacaine, fentanyl, methylprednisolone cefuroxime. The preoper- Multimodal approach ative pain of the patient was assessed using VAS score. Combined spinal and epidural anaesthesia was Perioperative analgesia given using 0.5% 2 ml of bupivacaine heavy in all patients. After taking bone cuts & before the placement Corticosteroids of the implant, cocktail of the drug was infiltrated using sterile technique into 9 specific sites.
  • Adverse Effects of Xenogenic Scaffolding in the Context of A

    Adverse Effects of Xenogenic Scaffolding in the Context of A

    Lamas et al. Trials (2019) 20:387 https://doi.org/10.1186/s13063-019-3504-3 RESEARCH Open Access Adverse effects of xenogenic scaffolding in the context of a randomized double-blind placebo-controlled study for repairing full- thickness rotator cuff tears José Ramón Lamas1†, Carlos García-Fernández2, Pilar Tornero-Esteban1, Yaiza Lópiz2, Luis Rodriguez-Rodriguez1, Luis Ortega3, Benjamín Fernández-Gutiérrez1*† and Fernando Marco2† Abstract Purpose: The purpose of the study was to compare the safety and efficacy of autologous mesenchymal stem cells (MSCs) embedded in a xenogenic scaffold for repairing the supraspinatus tendon. Methods: This was a randomized, double-blind and placebo-controlled trial evaluating patients with full-thickness rotator cuff tears (Eudra-CT, 2007–007630-19). Effectiveness was evaluated using the Constant score and a visual analogue pain scale (VAS). Constant score has four domains including pain (15 possible points), activities of daily living (20 possible points), mobility (40 possible points), and strength (25 possible points). Scores range from 0 points (most disability) to 100 points (least disability). The structural integrity of the repaired tendon was assessed by magnetic resonance imaging (MRI) according to Patte and Thomazeau classification criteria. The primary study end point was an improvement in the Constant score by 20 points at one year compared to initial assessment. Results: The trial was stopped due to adverse effects observed in both groups. Only thirteen patients were included and analyzed. The Constant questionnaire showed a significant improvement in the MSC treatment group compared with the preoperative data (p = 0.0073). Secondary outcome measures were similar in both groups.
  • Grade 6 Science Mechanical Mixtures Suspensions

    Grade 6 Science Mechanical Mixtures Suspensions

    Grade 6 Science Week of November 16 – November 20 Heterogeneous Mixtures Mechanical Mixtures Mechanical mixtures have two or more particle types that are not mixed evenly and can be seen as different kinds of matter in the mixture. Obvious examples of mechanical mixtures are chocolate chip cookies, granola and pepperoni pizza. Less obvious examples might be beach sand (various minerals, shells, bacteria, plankton, seaweed and much more) or concrete (sand gravel, cement, water). Mechanical mixtures are all around you all the time. Can you identify any more right now? Suspensions Suspensions are mixtures that have solid or liquid particles scattered around in a liquid or gas. Common examples of suspensions are raw milk, salad dressing, fresh squeezed orange juice and muddy water. If left undisturbed the solids or liquids that are in the suspension may settle out and form layers. You may have seen this layering in salad dressing that you need to shake up before using them. After a rain fall the more dense particles in a mud puddle may settle to the bottom. Milk that is fresh from the cow will naturally separate with the cream rising to the top. Homogenization breaks up the fat molecules of the cream into particles small enough to stay suspended and this stable mixture is now a colloid. We will look at colloids next. Solution, Suspension, and Colloid: https://youtu.be/XEAiLm2zuvc Colloids Colloids: https://youtu.be/MPortFIqgbo Colloids are two phase mixtures. Having two phases means colloids have particles of a solid, liquid or gas dispersed in a continuous phase of another solid, liquid, or gas.
  • 1 090304 Quiz 8 Introduction to Polymers (Chemistry) This Week We

    1 090304 Quiz 8 Introduction to Polymers (Chemistry) This Week We

    090304 Quiz 8 Introduction to Polymers (Chemistry) This week we ran a suspension polymerization to make polystyrene, a solution polymerization to make polyacrylamide and we discussed Ziegler-Natta polymerization to make polypropylene. 1) Suspension polymerization is similar to emulsion polymerization. a) Describe the importance of water to emulsion and suspension polymerization. Does water play an identical role in these two polymerizations? Is water a solvent? b) Describe the initiator that we used in suspension polymerization. What condition is needed to initiate this reaction? Why was a different initiator used in the emulsion polymerization? c) What is divinyl benzene and why is it included in this reaction? d) What controls the size of the polymer beads (droplet size) that result from suspension polymerization? e) What was the advantage of emulsion polymerization (over suspension polymerization) that lead to its development by Goodyear Tire and Rubber in the 1920’s? 2) Polyacrylamide is soluble in water as is the monomer acrylamide therefore this is a solution polymerization. a) Use the words ferric and ferrous to describe the initiator system for this polymerization. Why is this called a redox system? b) When hydrogen peroxide was added to the reaction mixture it turned from a faint bluish green to red (rust color). Later the color seemed to fade. Why did it change color? c) What temperature was needed to perform this polymerization? Why? d) How was polymer separated from the viscous reaction mixture after polymerization? e) Explain the disadvantage of solution polymerization compared to emulsion or suspension polymerization. 3) We looked at Ziegler-Natta polymerization briefly.
  • JMSCR Vol||05||Issue||01||Page 15625-15629||January 2017

    JMSCR Vol||05||Issue||01||Page 15625-15629||January 2017

    JMSCR Vol||05||Issue||01||Page 15625-15629||January 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i1.71 Transdermal Patch: A Comprehensive Overview of Newer Drug Delivery System in Modern Medical Science Authors Dr Neelkanth Kote1, Dr. Poornima B2 Department of Physiology and Department of Pharmacology Raja Rajeswari Medical Collegeand Hospital Bangalore, Karnataka– 560074 Corresponding Author Dr Neelkanth Kote Department of Physiology, RRMC Bangalore, Karnataka -560074 Email: [email protected] Abstract Background: Oral route of drug administration has been the most common route of drug administration since the beginning of the therapeuticarea in medical science. However this route of drug administration fails at bypassing the first pass metabolism of the drug in liver with poor bio availability. Oral route of drug administration also fails in uncooperative /unconscious semiconscious / pediatric subjects. Transdermal patch, a new drug delivery system through skin to the parenteral circulation has been the most recently discussed topic in pharmacology and medicine as it is a noninvasive route of drug administration, delivered in a sustained / pre fixed dosage with no / extremely less first pass metabolism and better bio availability. Most importantly it can be used in semiconscious / unconscious & pediatric subjects without affecting their hemodynamics. The transdermal patches have many beneficial factors however they also come with some major drawbacks like varieties of formulation, design and quality of adhesiveness. This articles provides an insight of transdermal patch in terms of its mechanism of action, advantages, disadvantages and future scope of it in the medical science.
  • Instruction Booklet ATTENTION: There Are 3 Critical Steps in the Reconstitution of Sandostatin® LAR

    Instruction Booklet ATTENTION: There Are 3 Critical Steps in the Reconstitution of Sandostatin® LAR

    Instruction Booklet ATTENTION: There are 3 critical steps in the reconstitution of Sandostatin® LAR. Not following them could result in failure to deliver the Preparation and Administration of drug appropriately. • The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. • After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum FOR DEEP INTRAGLUTEAL INJECTION ONLY of 2 minutes and up to 5 minutes. Read this entire booklet before proceeding. • After saturation, shake the vial moderately in a If you have questions about preparation and/or administration horizontal direction for a minimum of 30 seconds, until of Sandostatin® LAR Depot, please call 1-888-NOW-NOVA uniform suspension is formed. (1-888-669-6682). Instructions for gluteal Intramuscular (IM) Injection of Step 1 Sandostatin® LAR Depot (octreotide acetate) for injectable suspension • Remove the Sandostatin® LAR injection kit from Important Information for Health Care Professionals refrigerated storage. Successful preparation and administration ATTENTION: It is essential to start of Sandostatin® LAR Depot relies on proper the reconstitution process only after suspension technique. the injection kit has reached room Follow each of the steps outlined in this instruction booklet temperature. Let the kit stand to ensure complete saturation of the powder and its uniform at room temperature for a minimum suspension prior to deep intragluteal injection. of 30 minutes before reconstitution, but do not exceed 24 hours. It is critical that Sandostatin® LAR Depot and the diluent be allowed to reach room temperature and then be mixed Note: The injection kit can be re-refrigerated if needed.
  • INVEGA SUSTENNA® (Paliperidone Palmitate)

    INVEGA SUSTENNA® (Paliperidone Palmitate)

    INVEGA SUSTENNA® INVEGA SUSTENNA® (paliperidone palmitate) extended-release injectable suspension, for intramuscular use (paliperidone palmitate) extended-release injectable suspension, for intramuscular use --------------------------- DOSAGE FORMS AND STRENGTHS --------------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION Extended-release injectable suspension: 39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, These highlights do not include all the information needed to use 156 mg/mL, or 234 mg/1.5 mL (3) INVEGA SUSTENNA® safely and effectively. See full prescribing information for INVEGA SUSTENNA®. ----------------------------------- CONTRAINDICATIONS ----------------------------------- INVEGA SUSTENNA® (paliperidone palmitate) extended-release injectable Known hypersensitivity to paliperidone, risperidone, or to any excipients in suspension, for intramuscular use INVEGA SUSTENNA®. (4) Initial U.S. Approval: 2006 -----------------------------WARNINGS AND PRECAUTIONS ----------------------------- WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS • Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with WITH DEMENTIA-RELATED PSYCHOSIS Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse See full prescribing information for complete boxed warning. reactions (e.g. stroke, transient ischemic attack). (5.2) • Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of Elderly patients with dementia-related psychosis treated with antipsychotic drug and close monitoring. (5.3) drugs are
  • Chapter 18 Solutions and Their Behavior

    Chapter 18 Solutions and Their Behavior

    Chapter 18 Solutions and Their Behavior 18.1 Properties of Solutions Lesson Objectives The student will: • define a solution. • describe the composition of solutions. • define the terms solute and solvent. • identify the solute and solvent in a solution. • describe the different types of solutions and give examples of each type. • define colloids and suspensions. • explain the differences among solutions, colloids, and suspensions. • list some common examples of colloids. Vocabulary • colloid • solute • solution • solvent • suspension • Tyndall effect Introduction In this chapter, we begin our study of solution chemistry. We all might think that we know what a solution is, listing a drink like tea or soda as an example of a solution. What you might not have realized, however, is that the air or alloys such as brass are all classified as solutions. Why are these classified as solutions? Why wouldn’t milk be classified as a true solution? To answer these questions, we have to learn some specific properties of solutions. Let’s begin with the definition of a solution and look at some of the different types of solutions. www.ck12.org 394 E-Book Page 402 Homogeneous Mixtures A solution is a homogeneous mixture of substances (the prefix “homo-” means “same”), meaning that the properties are the same throughout the solution. Take, for example, the vinegar that is used in cooking. Vinegar is approximately 5% acetic acid in water. This means that every teaspoon of vinegar contains 5% acetic acid and 95% water. When a solution is said to have uniform properties, the definition is referring to properties at the particle level.
  • Ways to Physically Separate a Mixture There Are 2 Types of Mixtures

    Ways to Physically Separate a Mixture There Are 2 Types of Mixtures

    Mixtures 12 Mixtures Homogenous Compare Heterogeneous compounds and Suspension Mixtures. Colloid Solution Differentiate Solute/Solvent between solutions, suspensions, and colloids Comparing Mixtures and Compounds Mixtures Compounds Made of 2 or more substances Made of 2 or more substances physically combined chemically combined Substances keep their own properties Substances lose their own properties Can be separated by physical means Can be separated only by chemical means Have no definite chemical composition Have a definite chemical composition What method is used to separate mixtures Ways to physically separate a Mixture based on boiling • Distillation – uses boiling point point? • Magnet – uses magnetism What method is used • Centrifuge – uses density to separate mixtures based on density? • Filtering – separates large particles from smaller ones What method is used There are 2 types of mixtures: to separate mixtures (1) Heterogeneous Mixtures: the parts mixed together can still be based on particle size? distinguished from one another...NOT uniform in composition Give examples of a heterogeneous Examples: chicken soup, fruit salad, dirt, sand in water mixture Mixtures 12 (2) Homogenous Mixtures: the parts mixed together cannot be distinguished from one another...completely uniform in composition. Give examples of a homogenous Examples: Air, Kool-aid, Brass, salt water, milk mixture Differentiate Types of Homogenous mixtures between a homogenous 1. Suspensions mixture and a i.e. chocolate milk, muddy water, Italian dressing heterogeneous mixture. They are cloudy (usually a liquid mixed with small solid particles) Identify an example of a suspension. Needs to be shaken or stirred to keep the solids from Will the solid settling particles settle in a suspension? The solids can be filtered out 2.
  • Biphasic Dosage Forms Suspensions and Emulsions Unit 7

    Biphasic Dosage Forms Suspensions and Emulsions Unit 7

    BIPHASIC DOSAGE FORMS SUSPENSIONS AND EMULSIONS UNIT 7 Dr.N Damodharan Professor and Head Department of Pharmaceutics SRM College of Pharmacy Suspensions Heterogenous biphasic dosage form -- solid is dispersed in liquid medium. Dispersed phase, dispersion medium PROPERTIES: --Rapid settling ---Easily redisperdible,pourable ---if parenteral—flow through syringe needle ---if external---spread easily ---Pleasing in colour , odour, appearance. Types: ---Deflocculated ---Flocculated PROPERTIES: ---Interfacial property ---Electrical property zDispersions containing coarse particles, usually 10 to 50 um in size, are referred to as coarse dispersion. zDispersions containing particles of smaller size are termed fine dispersions (0.5 to 10 um) Suspensions In general sense, Suspension may include: ¾ Gels ¾ Lotions ¾ Magmas and Milk ¾ Mixtures Reasons for Suspensions ¾ Certain drugs are chemically unstable when in solution but stable when suspended. ¾ Suspension insures chemical stability while permitting liquid therapy. ¾ Many patients prefer liquid form than solid forms for swallowing. ¾ Convenience in administration ¾ Safety and convenience of liquid doses for infants and children. ¾ Disagreeable taste of certain drugs when given in solution is negligible when the drug is administered as undissolved particles of a suspension, e.g chloramphenicol Features Desired in a Pharmaceutical Suspensions 1. A properly prepared suspension should settle slowly and should be readily re- dispersed upon gentle shaking of the container. 2. The characteristics of the suspension should be such that the particles size of the suspensoid remains fairly constant throughout long periods of undisturbed standing. 3. The suspension should pour readily and evenly from its container Physical Features of the Dispersed Phase of a Suspension Good pharmaceutical suspensions, the particle diameter is between 1 to 50.